Valuation: Samik Pharmaceutical Company LTD.

Market Cap 55.74B 37.49M 32.76M 30.23M 27.86M 52.52M 3.61B 53.68M 361M 142M 1.77B 141M 138M 6.09B P/E 2024 *
-
P/E 2025 -140x
Enterprise Value 26.69B 17.95M 15.69M 14.47M 13.34M 25.15M 1.73B 25.71M 173M 68.05M 847M 67.41M 65.93M 2.91B EV / Sales 2024 *
-
EV / Sales 2025 1.65x
Free-Float
38.95%
Yield 2024 *
-
Yield 2025 -
1 day+29.84%
1 week+28.79%
Current month-13.91%
1 month-13.91%
3 months-47.25%
6 months-71.20%
Current year-60.13%
1 week 3,705
Extreme 3705
5,570
1 month 3,705
Extreme 3705
10,650
Current year 3,705
Extreme 3705
21,800
1 year 3,705
Extreme 3705
25,050
3 years 3,705
Extreme 3705
25,050
5 years 3,705
Extreme 3705
25,050
10 years 3,705
Extreme 3705
25,050
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2011
Chief Executive Officer 64 01/12/2016
Corporate Officer/Principal 56 01/08/2018
Director TitleAgeSince
Director/Board Member 72 01/03/2024
Chairman 64 01/12/2016
Chairman 59 01/06/2011
Change 5-day change 1-year change 3-year change Capi.($)
+29.84%+28.79% - - 37.49M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average +2.92%+3.36%+28.54%+53.91% 357.51B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2024 2025
Net sales 55.86B 37.56M 32.83M 30.29M 27.92M 52.63M 3.62B 53.8M 362M 142M 1.77B 141M 138M 6.1B 60.02B 40.36M 35.27M 32.55M 30M 56.55M 3.89B 57.8M 389M 153M 1.9B 152M 148M 6.55B
Net income 3.52B 2.37M 2.07M 1.91M 1.76M 3.32M 228M 3.39M 22.83M 8.98M 112M 8.9M 8.7M 385M -755M -508K -444K -409K -377K -711K -48.89M -727K -4.89M -1.92M -23.94M -1.91M -1.86M -82.43M
Net Debt -12.84B -8.64M -7.55M -6.96M -6.42M -12.1M -832M -12.37M -83.24M -32.74M -407M -32.43M -31.72M -1.4B -29.05B -19.54M -17.07M -15.75M -14.52M -27.37M -1.88B -27.98M -188M -74.07M -921M -73.37M -71.76M -3.17B
Logo Samik Pharmaceutical Company LTD.
Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The Company sells its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
16/07/26 ₩5,570.00 +29.84% 3,095,521
15/07/26 ₩4,290.00 +11.43% 2,382,100
14/07/26 ₩3,850.00 -3.51% 2,911,911
13/07/26 ₩3,990.00 -7.75% 158,943
10/07/26 ₩4,325.00 +4.34% 157,273
  1. Stock Market
  2. Stocks
  3. A014950 Stock